Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the Maui Derm Hawaii 2024 meeting, January 22-26, 2024. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring.
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the Maui Derm Hawaii 2024 meeting, January 22-26, 2024. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring.
Reaching Out to Improve Access to Radiation Therapy Treatment: Xstrahl attends regional conferences to meet with clinicians and discuss radiation therapy
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura, a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in San Diego, CA, October 1-3, 2023, booth #2216.
The Dermatology Insider 2023 is Xstrahl’s magazine for dermatologists. This issue of the Dermatology Insider includes patient stories about having SRT treatment for their skin cancer. In addition, hear from a dermatologist as he describes his experience using radiation therapy to treat non-melanoma skin cancer (NMSC). See two case history reports of radiation therapy treatment for skin cancer using SRT and eBt, detailing the number of treatments, dose per treatment, reasons for radiation therapy, as well as before and after images of the results. Xstrahl introduces Radiant Aura, which recently received US Food & Drug Administration (FDA) 510(k) Clearance. We share more about using Radiant Aura and answer the most commonly asked questions in our FAQ section.
Radiant™ Aura Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance
Expands office-based treatment options for millions of non-melanoma skin cancer (NMSC) patients
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, announced its Radiant™ Aura treatment solution has received U.S. Food and Drug Administration (FDA) 510(k) clearance. With advanced features for expanded clinical use, simplified patient positioning, and additional patient comfort, Radiant Aura brings radiation therapy to NMSC patients in any dermatology office.
Myrna has a history of multiple skin cancers that were treated with Mohs micrographic surgery. During the last year, Myrna was diagnosed twice with basal cell carcinomas (BCC). Her dermatologist, Dr. John Binhlam of Advanced Skin & Laser Center, in Brentwood, Tennessee recommended superficial radiation therapy (SRT) as an alternative to Mohs surgery based on several factors unique to her. Myrna had SRT treatment delivered with the RADiant system, right in Dr. Binhlam’s office.
Marcia is 74 years old and a great-grandmother from Bell Buckle, Tennessee. Last year, she noticed bleeding from a tiny spot on the tip of her nose. At her next appointment, she had her dermatologist, Dr. John Binhlam, take a closer look. He did a biopsy on the spot, and she was diagnosed with an invasive squamous cell carcinoma (SCC) of the nasal tip. After a discussion of Mohs micrographic surgery versus nonsurgical superficial radiation therapy (SRT), Marcia chose to have the latter treatment done using the RADiant system at his office, Advanced Skin & Laser Center in Brentwood, Tennessee.
Dermatologists are frequently leading the way in the diagnosis and management of non-melanoma skin cancer (NMSC). While Mohs surgery is the standard of care in the treatment of NMSC, the final decision on treatment for the patient should be based on their health, age,...
Contact Us